Biotech Bay
Filter News
Found 57,468 articles
-
The U.S. Food and Drug Administration approved Impact’s Inrebic for the treatment for adult patients with certain types of myelofibrosis, cancers of the bone marrow.
-
Although some of the top-selling drugs in the world are facing patent cliffs between now and then, many of them are still projected to continue being big sellers between now and 2024.
-
The FDA approved Rozlytrek for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer. Also, Rozlytrek secured accelerated approval for the treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance...
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Ultragenyx Inks a Partner-to-Buy Deal with GeneTx to Develop Treatment for Rare Genetic Syndrome
8/15/2019
Under the terms of the deal, Utragenyx will pay GeneTx $20 million for an exclusive option to acquire GeneTx. -
Accuray Reports Fourth Quarter and Fiscal 2019 Financial Results
8/15/2019
Revenue increased 3 percent to $117.4 million, the highest ever quarterly revenue reported; Gross orders increased to $97.2 million
-
AcelRx Pharmaceuticals Selected to Present at the 2019 Military Health System Research Symposium
8/15/2019
AcelRx was selected to present at one of the two plenary sessions at this year's meeting.
-
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis
8/15/2019
In early July, Gilead announced plans to submit a New Drug Application (NDA) for filgotinib for the treatment of RA in the United States before the end of the year.
-
FDA Approves Genentech’s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors
8/15/2019
First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain
-
MyoKardia Launches 2nd Annual MyoSeeds™ Research Grants Program to Advance Independent Research in Heart Disease
8/15/2019
Pre-Application Letters of Intent are Due September 13 for the 2019-2020 Funding Cycle
-
MyHealthTeams Raises $9.44 Million in Financing Round Led By Strategic Investor UCB
8/15/2019
Now serves more than 2 million registered members across 33 condition-specific patient social networks
-
Solv Health And Calibrator Health Partner To Offer Complete Patient Experience Solution For Urgent Care Centers
8/15/2019
Solv Health, the leading patient experience solution for urgent care centers, and Calibrater Health, the leading survey and feedback management platform for urgent care centers, today announced a data partnership that integrates the Solv platform with Calibrater patient survey data, enabling urgent care operators to gain an end-to-end view of their clinic performance.
-
Agilent Presents Thought Leader Award to Professor Gang Yu
8/15/2019
Agilent Technologies Inc. (NYSE: A) today announced that Dr. Gang Yu, a professor at the School of Environment at Tsinghua University in Beijing, China, has received an Agilent Thought Leader Award.
-
Agilent Introduces Revolutionary Real-Time Cell Analyzer
8/15/2019
Agilent Technologies Inc. (NYSE: A) today introduced a multimode real-time cell analyzer (RTCA)—the first of its kind—combining the best of non-invasive biosensor measurement with live cell imaging.
-
Nurx Secures $52 Million to Expand Access to Sensitive Health Needs
8/15/2019
Nurx, the health tech company providing convenient and affordable care for sensitive health needs, today announced it has raised an additional $52 million in funding.
-
Loop Genomics launches new de novo Bacterial Genome Assembly kits and service using long-reads on Illumina sequencers
8/15/2019
Loop Genomics, the single molecule long-read sequencing company with a hardware free solution, has expanded its kit and services capabilities to provide researchers with a new kit and service solution for de novo Bacterial Genome Assembly using long-reads on Illumina sequencers.
-
Ultragenyx Announces Partnership with GeneTx to Advance Treatment for Angelman Syndrome
8/14/2019
Ultragenyx Pharmaceutical Inc. and GeneTx Biotherapeutics LLC announced a partnership to develop GeneTx’s GTX-102, an antisense oligonucleotide (ASO) for the treatment of Angelman syndrome, a serious, debilitating, rare neurogenetic disorder that affects approximately 1 in 15,000 people worldwide.
-
Gritstone Oncology Announces First Patient Dosed with SLATE, its “Off-The-Shelf” Neoantigen Immunotherapy
8/14/2019
First patient dosed is a metastatic non-small cell lung cancer patient with a KRAS G12C mutation
-
Titan Pharmaceuticals Reports Second Quarter 2019 Financial Results
8/14/2019
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today reported financial results for the second quarter ended June 30, 2019 and provided an update on its business.
-
ACTenviro Makes Inc. 5000 List for 10th Time, Among Only 95 Ever To Do So
8/14/2019
Inc. magazine has, for the 10th year in a row, named ACTenviro to its annual 5000 list, the most prestigious ranking of the nation's fastest-growing private companies